OasisLMS

From Evidence to Action: Scaling Pharmacogenomics in Clinical Practice
Key Insights from the 2026 ACMG Annual Clinical Genetics Meeting- R. Rodney Howell Symposium

Tuesday, April 21, 2026 | 2:00 – 3:00 pm ET

1.0 AMA PRA Category 1 Credits™ and P.A.C.E.®

Session Description

Pharmacogenomics (PGx) offers the promise of improved medication safety and effectiveness through evidence-based genetic testing and prescribing guidance. While many institutions have demonstrated feasibility, scaling PGx across complex health systems requires coordinated strategies in laboratory operations, clinician education, informatics infrastructure, and clinical decision support.

This focused webinar distills key implementation lessons from national leaders featured in the 2026 ACMG Annual Clinical Genetics Meeting R. Rodney Howell Symposium. Participants will explore practical approaches that have successfully moved pharmacogenomics from pilot programs to sustained clinical integration.

Preparatory Material (Optional)
Participants are encouraged to watch the two-hour recording of the R. Rodney Howell Symposium (presented March 14, 2026, at the ACMG Annual Meeting in Baltimore) prior to attending.

Join the live webinar for a focused discussion of key insights and practical strategies for scaling pharmacogenomics in clinical practice.

Learning Objectives

At the conclusion of this activity, participants should be able to:

Identify key operational and systems-level barriers to implementing pharmacogenomics programs at scale across health systems.

Apply practical strategies for integrating pharmacogenomics into clinical workflows, including laboratory test development, education models, and electronic health record/clinical decision support tools.

Evaluate scalable care delivery models that support sustainable and guideline-concordant pharmacogenomics practice.

Target Audience

This activity is designed for healthcare professionals involved in the implementation and integration of pharmacogenomics into clinical practice, including:

• Clinical and Medical Geneticists
• Laboratory Directors and Clinical Laboratory Professionals
• Pharmacists and Pharmacogenomics Specialists
• Physicians across specialties (e.g., cardiology, oncology, psychiatry, primary care) who utilize or plan to incorporate PGx-guided therapy
• Genetic Counselors
• Clinical informatics and health IT professionals (EHR/clinical decision support)
• Healthcare administrators and program leaders responsible for precision medicine or genomic service line development
• Researchers and implementation scientists focused on translational genomics

Agenda

Welcome and Framing: From Evidence to Action
Philip E. Empey, PharmD, PhD

Segment 1: Defining Value and Measuring Impact in Pharmacogenomics
Deepak Voora
Philip E. Empey, PharmD, PhD

Segment 2: Building and Sustaining PGx Infrastructure
Laboratory Development, Education Models, and Scalable Implementation
Sherin Shaaban, MD, PhD, FACMG
Philip E. Empey, PharmD, PhD

Segment 3: Translating Evidence into Clinical Practice
Guidelines, Clinical Decision Support, and Workflow Integration
Cyrine Haidar, PharmD
Henry M. Dunnenberger

Segment 4: Managing Growth and Continuous Change in PGx Programs
Henry M. Dunnenberger
Deepak Voora

Integrated Panel Discussion: Lessons Learned and Practical Strategies for Scaling PGx
All Faculty

Audience Q&A

Meet the Faculty

Philip Empey

Dr. Philip Empey is the Associate Director of the Institute for Precision Medicine at the University of Pittsburgh and UPMC and an Associate Professor in the School of Pharmacy. He directs the Pharmacogenomics Center of Excellence and leads the PreCISE-Rx and Test2Learn teams to implement pharmacogenomics clinical, research, and educational initiatives. As a clinician-scientist, Dr. Empey conducts NIH-funded clinical and translational research aimed at understanding the mechanisms of the variability in drug response to improve medication-related outcomes.

Deepak Voora

Deepak Voora, MD, is Professor of Medicine at Duke University School of Medicine and a staff cardiologist at the Durham Veterans Affairs Medical Center. In addition, Dr. Voora is the Executive Director for the VA's National Pharmacogenomics Program, Dr. Voora is leading the implementation of pharmacogenomics testing and clinical services in the nation's largest integrated health care system. At the VA, his goal is to build and to implement the necessary infrastructure, systems, and personnel required for appropriate and effective use of pharmacogenomics testing enterprise wide. His research focusses on the discovery and translation of pharmacogenomic biomarkers to improve health and economic outcomes. He has focused on some of the most prescribed medications worldwide – antiplatelets, statins, antidepressants, and opioids – for his research.

Sherin Shaaban

Dr. Shaaban is an Associate Professor of Pathology at the University of Utah School of Medicine, and the Medical Director of Pharmacogenomics and Molecular Genetics at ARUP. She graduated from Mansoura University Medical School in Egypt, then obtained her PhD in Human Genetics at the Graduate School of Medicine Dentistry and Pharmaceutical Science at Okayama University in Japan. After a few years as a genetics research fellow at Harvard Medical School and Boston Children's Hospital, she went on to finish a clinical molecular genetics fellowship at Mount Sinai School of Medicine, Department of Genetics and Genomics.
Dr. Shaaban is board certified by American Board of Medical Genetics and Genomics and is a fellow of the American College of Medical Genetics and Genomics

Cyrine Haidar

Dr. Haidar is an Associate Member in the Department of Pharmacy and Pharmaceutical Sciences at St. Jude Children's Research Hospital. She received her Pharm.D. from the Lebanese American University in Byblos, Lebanon and completed a Pharmacotherapy residency at Hackensack University Medical Center in New Jersey followed by a Pediatric Oncology Residency at St. Jude. Her practice is focused on the clinical implementation of pharmacogenomics where she has helped institutions across the world offer pharmacogenomic testing services to their patients. Dr. Haidar is the Immediate Past Chair of the Board of Pharmacy Specialties (BPS) Board of Directors, a current member of the Genetics and Genomics Steering Board of Epic, and the co-lead of the Pharmacogenomics Brain Trust of Epic. Dr. Haidar is an active member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and has authored more than 7 CPIC guidelines to date. She is a contributing editor for pharmacogenomics of the American Journal of Health-System Pharmacy.

Henry Dunnenberger

Dr. Dunnenberger is Assistant Vice President - Personalized Medicine in the Mark R. Neaman Center for Personalized Medicine and Medical Director of the Davis Family Center for Preventive Genomics at Endeavor Health (Endeavor), and leads the various clinical genomics implementation projects, including pharmacogenomics, as the health system. The goal of these projects is to improve the care and health outcomes of Endeavor Health patients through genomic and pharmacogenomics-based strategies. He joined Endeavor in 2014.

Dr. Dunnenberger leads the Pharmacogenomics Clinic, which serves as part of a system-wide initiative building upon the health system's strong foundation in genetics and molecular medicine. His clinical expertise and research interests include translating pharmacogenomics into clinical practice, developing information technology solutions for delivering genetic information to both clinicians and patients in a practical manner, and evaluating methods for educating healthcare professionals about pharmacogenetics

Dr. Dunnenberger has co-authored over 50 original publications, including multiple CPIC guidelines. He earned his PharmD from the University of Tennessee Health Science Center College of Pharmacy in 2012. He completed a PGY1 Pharmacy Practice Residency at Mission Hospital in Asheville, North Carolina, and a PGY2 Clinical Pharmacogenetics Residency in the Department of Pharmaceutical Sciences at St. Jude Children's Research Hospital in Memphis, Tennessee.

Accredited Continuing Education Information:

AMA PRA Category 1 Credit^TM, ASCLS P.A.C.E.^®

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.

ASCLS P.A.C.E.® CEU's 

ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program.

ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider (50-11878). ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.® (275-200-26-02). This activity has been approved for 0.10 P.A.C.E.® CEU's.

Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days from the date of the activity. Educational credit requests after this date will not be accepted.

Learner Data Consent

ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.

Technical Support:
You can reach us by email at education@acmg.net or call 301-718-9603.
Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.

*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships listed have been mitigated.